Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study

Abstract

Background Cancer survivors are frequently excluded from clinical research, resulting in their omission from the development of many cancer treatment strategies. Quantifying the prevalence of prior cancer in newly diagnosed cancer patients can inform research and clinical practice. This study aimed to describe the prevalence, characteristics, and trends of prior cancer in newly diagnosed cancer patients in Japan. Methods Using Osaka Cancer Registry data, we examined the prevalence, characteristics, and temporal trends of prior cancer in patients who received new diagnoses of lung, stomach, colorectal, female breast, cervical, and corpus uterine cancer between 2004 and 2015. Site-specific prior cancers were examined for a maximum of 15 years before the new cancer was diagnosed. Temporal trends were evaluated using the Cochran-Armitage trend test. Results Among 275,720 newly diagnosed cancer patients, 21,784 (7.9%) had prior cancer. The prevalence of prior cancer ranged from 3.3% (breast cancer) to 11.1% (lung cancer). In both sexes, the age-adjusted prevalence of prior cancer had increased in recent years (P values for trend < 0.001), especially in newly diagnosed lung cancer patients. The proportion of smoking-related prior cancers exceeded 50% in patients with newly diagnosed lung, stomach, colorectal, breast, and cervical cancer. Conclusions The prevalence of prior cancer in newly diagnosed cancer patients is relatively high, and has increased in recent years. Our findings suggest that a deeper understanding of the prevalence and characteristics of prior cancer in cancer patients is needed to promote more inclusive clinical research and support the expansion of treatment options.

Second primary cancer among 217702 colorectal cancer survivors: An analysis of national German cancer registry data

“…30 The increased SPC risk particularly in the age group 50-64 is possibly due to increased medical surveillance following cancer screening, which may lead to more incidental detection of subsequent cancers. 31 Although we observed a median latency period of 4.7 years between primary CRC and SPC for this age group, this was shortened for clinically relevant surveillance sites such as the colon and rectum where recurrence or second primary CRC are commonly found 17 and was longer (more than 5 years) for other sites where other cancer screenings are recommended, for example mammography. 32 Older age (above 65 years) is also associated with increased cancer risk owing to age-related cancers.…”

“…The incidence of CRC diagnoses in this same period (1977 to 2012) increased by roughly 1.5‐fold for both men and women following screening introduction, peaking around the early 2000s 30 . The increased SPC risk particularly in the age group 50‐64 is possibly due to increased medical surveillance following cancer screening, which may lead to more incidental detection of subsequent cancers 31 . Although we observed a median latency period of 4.7 years between primary CRC and SPC for this age group, this was shortened for clinically relevant surveillance sites such as the colon and rectum where recurrence or second primary CRC are commonly found 17 and was longer (more than 5 years) for other sites where other cancer screenings are recommended, for example mammography 32 .…”

Revisiting Exclusion of Prior Cancer in Clinical Trials of Male Breast Cancer

“…Notably, (Table 1 ) most men with prior cancer were previously diagnosed with a different type of cancer, fewer had a prior breast cancer. Prior cancer prevalence is rising and is anticipated to continue to increase due to early detection, advanced therapies 13 , 14 , and an aging population.…”

“…Notably, (Table 1) most men with prior cancer were previously diagnosed with a different type of cancer, fewer had a prior breast cancer. Prior cancer prevalence is rising and is anticipated to continue to increase due to early detection, advanced therapies [13,14], and an aging population. The practice of excluding individuals with prior cancer from clinical trials limits trial accrual and generalizability of findings, and it substantially affects trials of rare cancers diagnosed among older adults where accrual is difficult.…”

Management of patients with multiple primary сancer in the practice of a modern oncologist. Case report and literature review

“…Еще одна связь между первичным онкологическим процессом и развитием «второй» опухоли прослеживается в общности факторов риска последних. Например, таких как курение и употребление алкоголя: данные факторы приводят к развитию синхронного или метахронного рака в полости рта или/и пищевода [10,11]. Общепризнанным и значимым фактором риска развития ПМЗО является пожилой возраст [12].…”